Swiss Pharma Nigeria Limited (Swipha) has achieved a significant milestone by receiving World Health Organisation (WHO) prequalification for its Sulfadoxine Plus Pyrimethamine (SP) 500/25mg tablet, specifically designed to combat malaria in pregnancy. This marks a historic first for the Nigerian pharmaceutical company, underscoring its dedication to improving maternal health.
Malaria continues to be a critical public health challenge, particularly in sub-Saharan Africa, where pregnant women and young children are most at risk. The use of SP during antenatal care is vital in preventing severe complications such as maternal anaemia, low birth weight, and preterm births.
Frederic Lieutaud, Managing Director of Swipha, emphasized that this accomplishment reflects the company’s commitment to providing high-quality, life-saving medicines that adhere to international safety and efficacy standards. Swipha’s Business Development & Licensing Director, Abbas Sambo, highlighted that the WHO prequalification enables the company to distribute the SP Tablet globally, enhancing maternal and child health outcomes.
NAFDAC praised Swipha for its dedication to maintaining stringent quality control and compliance with Good Manufacturing Practice (GMP) standards. This achievement sets a benchmark for other local pharmaceutical manufacturers, encouraging them to pursue similar certifications and improve the quality of medicines available in Nigeria and the broader region.
